Harrow (Nasdaq: HROW), a leading US eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic prescription therapies, has announced that it has entered into a US$100 million secured credit financing agreement with funds managed by Oaktree Capital Management, L.P. (Oaktree), a leader among global investment managers specializing in alternative investments.
Latham & Watkins LLP advises Oaktree in the financing with a deal team led by Bay Area partner Haim Zaltzman and Los Angeles/Bay Area partner Elizabeth Oh, with associate Benjamin Gelfand. Advice was also provided on corporate matters by Bay Area partner Jim Morrone; on tax matters by Bay Area partner Katharine Moir, with associate Alex Farris; on healthcare matters by Washington, D.C. partner Stuart Kurlander and Bay Area partner Betty Pang, with associate Lee Staley; on FDA matters by Washington, D.C. partner Ben Haas, with associate Seth Olson; and on other matters by Los Angeles partner Nima Mohebbi.
